JP Morgan Chase’s BioNexus Gene Lab BGLC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3 Buy
+2
New +$3 ﹤0.01% 8145
2025
Q1
– Sell
-58
Closed -$162 – 7342
2024
Q4
$162 Buy
+58
New +$191 ﹤0.01% 6939

Other funds holding BGLC

JP Morgan Chase's BGLC Position: Q3 2026 in Review

JP Morgan Chase opened a new position in BioNexus Gene Lab (BGLC) in Q3 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #8145 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in BGLC as recently as Q4 2024.

JP Morgan Chase first reported a position in BGLC in Q4 2024 and has held it in 2 quarters since. The position peaked at $162 in Q4 2024. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2026.

  • JP Morgan Chase held 2 shares of BioNexus Gene Lab worth $3 as of Q3 2026.
  • BioNexus Gene Lab was a new JP Morgan Chase position in Q3 2026.
  • BioNexus Gene Lab made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8145 holding.
  • JP Morgan Chase first reported a position in BioNexus Gene Lab in Q4 2024 and has held it in 2 quarters since.
  • JP Morgan Chase's BioNexus Gene Lab position peaked at $162 in Q4 2024.
  • 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.